Literature DB >> 11747348

Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells.

B Wen1, E Deutsch, E Marangoni, V Frascona, L Maggiorella, B Abdulkarim, N Chavaudra, J Bourhis.   

Abstract

Insulin-like growth factor-1 (IGF-1) plays an important growth-promoting effect by activating the PI3K/Akt signalling pathway, inhibiting apoptotic pathways and mediating mitogenic actions. Tyrphostin AG 1024, one selective inhibitor of IGF-1R, was used to evaluate effects on proliferation, radiosensitivity, and radiation-induced cell apoptosis in a human breast cancer cell line MCF-7. Exposure to Tyrphostin AG 1024 inhibited proliferation and induced apoptosis in a time-dependent manner, and the degree of growth inhibition for IC20 plus irradiation (4 Gy) was up to 50% compared to the control. Examination of Tyrphostin AG 1024 effects on radiation response demonstrated a marked enhancement in radiosensitivity and amplification of radiation-induced apoptosis. Western blot analysis indicated that Tyrphostin AG 1024-induced apoptosis was associated with a downregulation of expression of phospho-Akt1, increased expression of Bax, p53 and p21, and a decreased expression of bcl-2 expression, especially when combined with irradiation. To our knowledge, this is the first report showing that an IGF-1 inhibitor was able to markedly increase the response of tumour cells to ionizing radiation. These results suggest that Tyrphostin AG 1024 could be used as a potential therapeutic agent in combination with irradiation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747348      PMCID: PMC2364012          DOI: 10.1054/bjoc.2001.2171

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

Review 1.  Differential regulation of signaling pathways for insulin and insulin-like growth factor I.

Authors:  W Lopaczynski
Journal:  Acta Biochim Pol       Date:  1999       Impact factor: 2.149

Review 2.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

3.  Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF-7 breast cancer cells.

Authors:  S Monno; M V Newman; M Cook; W L Lowe
Journal:  Endocrinology       Date:  2000-02       Impact factor: 4.736

4.  Loss of local control with prolongation in radiotherapy.

Authors:  J F Fowler; M J Lindstrom
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.

Authors:  Z Q Yuan; M Sun; R I Feldman; G Wang; X Ma; C Jiang; D Coppola; S V Nicosia; J Q Cheng
Journal:  Oncogene       Date:  2000-05-04       Impact factor: 9.867

6.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

7.  Nonradioactive labeling of oligonucleotides in vitro with the hapten digoxigenin by tailing with terminal transferase.

Authors:  G G Schmitz; T Walter; R Seibl; C Kessler
Journal:  Anal Biochem       Date:  1991-01       Impact factor: 3.365

8.  The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components.

Authors:  J Dupont; M Karas; D LeRoith
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

9.  Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.

Authors:  A Gazit; P Yaish; C Gilon; A Levitzki
Journal:  J Med Chem       Date:  1989-10       Impact factor: 7.446

10.  Association of insulin-like growth-factor-I-induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF-7 cells.

Authors:  K Takahashi; K Suzuki
Journal:  Int J Cancer       Date:  1993-09-30       Impact factor: 7.396

View more
  25 in total

Review 1.  Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Authors:  Deepali Sachdev; Douglas Yee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

Review 2.  Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling.

Authors:  David N Boone; Adrian V Lee
Journal:  Crit Rev Oncog       Date:  2012

3.  Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1.

Authors:  Ying Wang; David M Lonard; Yang Yu; Dar-Chone Chow; Timothy G Palzkill; Bert W O'Malley
Journal:  Mol Endocrinol       Date:  2011-11-03

Review 4.  Nutrient restriction and radiation therapy for cancer treatment: when less is more.

Authors:  Colin E Champ; Renato Baserga; Mark V Mishra; Lianjin Jin; Federica Sotgia; Michael P Lisanti; Richard G Pestell; Adam P Dicker; Nicole L Simone
Journal:  Oncologist       Date:  2013-01-08

Review 5.  The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.

Authors:  Morteza Motallebnezhad; Leili Aghebati-Maleki; Farhad Jadidi-Niaragh; Hamid Nickho; Hosein Samadi-Kafil; Karim Shamsasenjan; Mehdi Yousefi
Journal:  Tumour Biol       Date:  2016-07-21

6.  Growth factor receptors signaling in glioblastoma cells: therapeutic implications.

Authors:  Mia Carapancea; Oana Alexandru; Ani S Fetea; Laura Dragutescu; Juan Castro; Ada Georgescu; A Popa-Wagner; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2008-11-30       Impact factor: 4.130

Review 7.  Receptor signaling as a regulatory mechanism of DNA repair.

Authors:  Raymond E Meyn; Anapama Munshi; John V Haymach; Luka Milas; K Kian Ang
Journal:  Radiother Oncol       Date:  2009-07-15       Impact factor: 6.280

Review 8.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

Review 9.  Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.

Authors:  Kevin C J Yuen; Anthony P Heaney; Vera Popovic
Journal:  Endocrine       Date:  2016-01-05       Impact factor: 3.633

10.  Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism.

Authors:  Gurpreet S Baht; Akshay Bareja; David E Lee; Rajesh R Rao; Rong Huang; Janet L Huebner; David B Bartlett; Corey R Hart; Jason R Gibson; Ian R Lanza; Virginia B Kraus; Simon G Gregory; Bruce M Spiegelman; James P White
Journal:  Nat Metab       Date:  2020-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.